ribavirin has been researched along with eicosapentaenoic acid in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Okamura, T; Sata, M; Seki, R; Tanaka, K | 1 |
| Hara, Y; Hino, K; Kawakami, T; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M | 1 |
| Kakibuchi, N; Kawakami, T; Kita, K; Murakami, Y; Okita, M; Takaguchi, K; Tomioka, K | 1 |
| Furutani, T; Hara, Y; Hino, K; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M; Ren, F; Yamaguchi, Y; Yamashita, S; Yutoku, K | 1 |
| Ide, T; Kage, M; Maruyama, T; Okamura, T; Sata, M; Seki, R; Uyesaka, N | 1 |
| Aikata, H; Aimitsu, S; Chayama, K; Imamura, M; Ishihara, H; Kawakami, H; Kawakami, Y; Kitamoto, M; Moriya, T; Nakanishi, T; Satoh, K; Takahashi, S; Takaki, S; Tsuji, K | 1 |
| Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K; Tsukamoto, I | 1 |
| Inage, E; Minowa, K; Naritaka, N; Ohtsuka, Y; Saito, N; Shimizu, T; Suzuki, M; Tokita, A; Tsubahara, M | 1 |
| Aoyagi, Y; Enjoji, M; Fujino, T; Fukuizumi, K; Fukushima, N; Harada, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M; Sakamoto, N; Tanaka, Y; Yada, M; Yada, R; Yoshimoto, T | 1 |
| Mahmoud, M; Morsy, KH; Zaghloul, A | 1 |
7 trial(s) available for ribavirin and eicosapentaenoic acid
| Article | Year |
|---|---|
Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Vitamin E; Vitamins | 2006 |
Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Deoxyguanosine; Dietary Supplements; Eicosapentaenoic Acid; Erythrocyte Membrane; Erythrocytes; Fatty Acids; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Phospholipids; Recombinant Proteins; Ribavirin | 2005 |
Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients.
Topics: alpha-Tocopherol; Ascorbic Acid; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Membrane; Female; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome | 2006 |
Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability.
Topics: Adult; Aged; Anemia, Hemolytic; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes; Hemorheology; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Topics: Adult; Aged; Anemia; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
Topics: Adolescent; Anemia; Antiviral Agents; Child; Child, Preschool; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Young Adult | 2012 |
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
4 other study(ies) available for ribavirin and eicosapentaenoic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Eicosapentaenoic Acid; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin.
Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin E | 2008 |
Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quinolines; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |